All In Biotech

Drug Trial Radar · NCT04308681

A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants With Pulmonary Fibrosis

Last checked: Nov 19, 2026Latest source record: Feb 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 403 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

403

Actual

Start

Jul 29, 2020

Primary completion

Aug 4, 2022

Study completion Sep 22, 2023

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Mar 16, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to provide an initial evaluation of the effectiveness of BMS-986278 in participants with lung fibrosis, to demonstrate the safety of BMS-986278, and provide information on the drug levels of BMS-986278 in these participants.

Conditions

  • Pulmonary Fibrosis

Interventions

  • BMS-986278 PlaceboOther

    Specified Dose on Specified Days

  • BMS-986278Drug

    Specified Dose on Specified Days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Percent Predicted Forced Vital Capacity (ppFVC) in IPF ParticipantsTime frame: From baseline (first dose) up to week 26

Locations

119 sites in 18 countries. Site status is shown where the registry gives one.

  • Local Institution - 0032

    Birmingham, Alabama

  • Local Institution

    Phoenix, Arizona

  • Local Institution - 0028

    Los Angeles, California

  • Local Institution - 0043

    Stanford, California

  • University of Colorado Anschutz Medical Campus-Department of Medicine

    Aurora, Colorado

  • Local Institution - 0006

    Denver, Colorado

  • Local Institution - 0171

    New Haven, Connecticut

  • Local Institution - 0035

    Gainesville, Florida

  • Local Institution - 0166

    Orlando, Florida

  • Local Institution - 0078

    Atlanta, Georgia

  • Local Institution - 0031

    Kansas City, Kansas

  • Local Institution - 0154

    Baltimore, Maryland

  • Local Institution - 0003

    Boston, Massachusetts

  • Local Institution - 0030

    Chesterfield, Missouri

  • Local Institution - 0036

    St Louis, Missouri

  • Local Institution - 0029

    Cincinnati, Ohio

  • Local Institution - 0164

    Columbus, Ohio

  • Local Institution

    Hershey, Pennsylvania

  • Local Institution

    Nashville, Tennessee

  • Local Institution - 0096

    Charlottesville, Virginia

  • Local Institution

    Falls Church, Virginia

  • Local Institution - 0115

    Buenos Aires, Argentina

  • Local Institution - 0048

    Buenos Aires, Argentina

  • Local Institution - 0122

    Mendoza, Argentina

  • Local Institution - 0049

    Buenos Aires, Distrito Federal, Argentina

  • Local Institution - 0103

    Rosario, Santa Fe Province, Argentina

  • Local Institution - 0097

    San Miguel de Tucumán, Tucumán Province, Argentina

  • Local Institution - 0045

    Camperdown, New South Wales, Australia

  • Local Institution - 0025

    Westmead, New South Wales, Australia

  • Local Institution - 0026

    Brisbane, Queensland, Australia

  • Local Institution - 0046

    Greenslopes, Queensland, Australia

  • Local Institution - 0022

    Adelaide, South Australia, Australia

  • Local Institution - 0023

    Heidelberg, Victoria, Australia

  • Local Institution - 0021

    Murdoch, Western Australia, Australia

  • Local Institution - 0044

    Nedlands, Western Australia, Australia

  • Local Institution - 0074

    Brussels, Belgium

  • Local Institution - 0065

    Leuven, Belgium

  • Local Institution - 0051

    Liège, Belgium

  • Local Institution - 0076

    São Paulo, Brazil

  • Local Institution

    Porto Alegre, Rio Grande do Sul, Brazil

Showing 40 of 119 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.